Innoviva is focused on royalty management. The company's Long-Acting Beta2 Agonist (LABA) collaboration has developed three combination products: RELVAR?/BREO? ELLIPTA? fluticasone furoate/ vilanterol, FF/VI), a once-daily combination medicine consisting of a LABA, VI, and an inhaled corticosteroid (ICS), FF; ANORO? ELLIPTA? (UMEC/VI), a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI, and; TRELEGY? ELLIPTA? (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA and LABA.
  • TickerINVA
  • ISINUS45781M1018
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

ValuEngine Rating and Forecast Report for INVA

Innoviva, Inc.: Update to credit analysis

Our credit view of Innoviva, reflecting strong cash flow but significant revenue concentration.

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

2 directors bought/sold after exercising options

Two Directors at Innoviva Inc bought/sold after exercising options 11,353 shares at between 14.670USD and 14.896USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is ...